scholarly journals COMPARISON OF CLINICAL EFFICACY OF ORIGINAL BISOPROLOL AND ITS GENERIC DRUG IN PATIENTS WITH STABLE ANGINA AND CONCOMITANT CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2010 ◽  
Vol 6 (4) ◽  
pp. 497-501
Author(s):  
N. Yu. Grigorieva ◽  
E. G. Sharabrin ◽  
A. N. Kuznetsov
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Clinical Efficacy ◽  
Generic Drug ◽  
Stable Angina ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals Some aspects of stable angina treatment: risk of complications assessment in a combined course with COPD

2014 ◽  
Vol 18 (4 (72)) ◽  
Author(s):  
V. K. Tashchuk ◽  
T. N. Amelinа ◽  
A. S. Polianska ◽  
О. I. Hulaga
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Stable Angina ◽  
Pulmonary Ventilation ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Treatment Risk

The effect of carvedilol on indices of pulmonary ventilation in patients with stable angina in combination with chronic obstructive pulmonary disease and the expediency of its function during stable remission comorbidity has been studied.

scholarly journals A Prediction Model for Intermediate- and High-risk Pulmonary Hypertension During the Acute Exacerbation of Chronic Obstructive Pulmonary Disease

2021 ◽  
Author(s):  
Xilian Feng ◽  
Jiahua Liang ◽  
Jiamin Chen ◽  
Weiyan Chen ◽  
Hui Li ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Hypertension ◽  
High Risk ◽  
Prediction Model ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Clinical Efficacy ◽  
Chronic Obstructive ◽  
Discriminative Ability ◽  
Obstructive Pulmonary Disease

Abstract Background: Pulmonary hypertension (PH) is a serious complication of COPD and is associated with poor prognosis. There are currently no established predictive models for PH during the acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Objective: To establish a prediction model for intermediate- and high-risk PH in AECOPD patients.Methods: This study collected data from 203 AECOPD patients and divided the patients into a model group and an external validation group. The influence of each parameter on PH was analysed through univariate and multivariate analyses, and these data were used to build a prediction model. Finally, the discriminative ability, calibration ability and clinical efficacy of the model were tested.Result: Age, RDW-CV and RDW-SD were related to PH, so these variables were used to establish a prediction model. In addition, the discriminative ability, calibration ability and clinical efficacy of the model were affirmed.Conclusion: This study established a clinical prediction model for AECOPD patients with PH, and the prediction model has certain clinical value for assisting in the screening of intermediate- and high-risk patients with PH.

scholarly journals The Clinical Efficiency and the Mechanism of Sanzi Yangqin Decoction for Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 2021 ◽  
pp. 1-21
Author(s):  
Mengqi Wang ◽  
Wenwen Gu ◽  
Fuguang Kui ◽  
Fan Gao ◽  
Yuji Niu ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Molecular Docking ◽  
Pulmonary Disease ◽  
Clinical Efficacy ◽  
Network Pharmacology ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Volume Percentage ◽  
The Core

This work is carried out to evaluate the clinical efficacy of Sanzi Yangqin decoction (SZYQD) treating chronic obstructive pulmonary disease (COPD) and to analyze its mechanism. The clinical efficacy of SZYQD treating COPD was evaluated by meta-analysis, and its mechanism was analyzed by network pharmacology. Molecular docking validation of the main active compounds and the core targets was performed by AutoDock vina software. A cigarette smoke (CS) and LPS-induced COPD model in ICR mice was constructed to confirm the effects of luteolin on COPD. Results showed that SZYQD has a greater benefit on the total effect (OR = 3.85, 95% CI [3.07, 4.83], P = 1 ) in the trial group compared with the control group. The percentage of forced expiratory volume in one second (FEV1%) (MD = 0.5, 95% CI [0.41, 0.59], P < 0.00001 ) and first seconds breathing volume percentage of forced vital capacity (FEV1%/FVC) were improved (MD = 5.97, 95% CI [3.23, 8.71], P < 0.00001 ). There are 27 compounds in SZYQD targeting 104 disease targets related to COPD. PPI network analysis indicated that EGFR, MMP9, PTGS2, MMP2, APP, and ERBB2 may be the core targets for the treatment of COPD. Molecular docking demonstrated that luteolin in SZYQD showed the strongest binding activity to core targets. Experimental results revealed that the expression of COPD-related targets in lung tissue was significantly increased in the COPD group and was improved in the luteolin group. Our data indicated that SZYQD has a curative effect on COPD and luteolin is a candidate compound for COPD treatment by regulating EGFR, MMP9, PTGS2, MMP2, APP, and ERBB2.

scholarly journals ENDOTHELIAL DYSFUNCTION IN STABLE ANGINA AND MYOCARDIAL INFARCTION COMBINED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2015 ◽  
Vol 14 (6) ◽  
pp. 68-74 ◽  
Author(s):  
M. A. Popova ◽  
N. N. Terentyeva ◽  
D. A. Dolgopolova ◽  
T. V. Marenina
Keyword(s):  
Myocardial Infarction ◽  
Chronic Obstructive Pulmonary Disease ◽  
Endothelial Dysfunction ◽  
Pulmonary Disease ◽  
Stable Angina ◽  
Forced Expiratory Volume ◽  
Chronic Obstructive ◽  
Cross Sectional ◽  
Brachial Artery Diameter ◽  
Obstructive Pulmonary Disease

The research objective is to determine the state of endothelium-dependent and endothelium-independent vasodilatation in patients with coronary heart disease (CHD) associated with chronic obstructive pulmonary disease (COPD).Material and methods. In the cross-sectional study included 122 patients with CHD associated with COPD: 68 people of them are patients with stable angina without acute coronary events in history and 54 patients with acute ST segment elevation myocardial infarction (STEMI). Comparison group comprised 53 patients with stable angina and 51 patients after STEMI without concomitant COPD. Patients were included if they met the following inclusion criteria: male, age <60 years, verified forms of CHD (stable angina, STEMI), documented with COPD without exacerbation and forced expiratory volume in 1 second > 30% in the groups with CHD and COPD. Arterial endothelial function was tested with high-resolution ultrasonography: brachial artery diameter was measured at rest, after flow increase (which causes endothelium-dependent dilatation), and after administration of sublingual nitroglycerin (an endothelium-independent dilator).Results. We found that endothelial dysfunction in patients with acute and chronic forms of CHD in combination with COPD are more pronounced than in isolated CHD.Conclusion. Expressed depression functional vascular reserve in patients with CHD associated with COPD, should be taken into account when conducting individualized therapy of these patients.

Sign in / Sign up

Export Citation Format

Share Document